Pretreatment with chemotherapy in patients with advanced head and neck cancer.
Average survival for advanced head and neck cancer (AHNC) is 18 months. In an attempt to improve this we treated 29 AHNC patients between 1978-82 with two courses of chemotherapy. Chemotherapy consisted of cyclophosphamide, methotrexate, 5 fluorouracil and bleomycin; or bleomycin, cisplatinum and methotrexate. Chemotherapy was given prior to definitive therapy of radiotherapy or radiotherapy and surgery. All patients were stage 3 or 4. All patients were Eastern Co-operative Oncology Group status performance 0 or 1. Response to chemotherapy did not improve survival. Pretreatment with chemotherapy should be investigational until increased survival has been documented.
Cripps
C
C
Odell
P
P
Danjoux
C
C
Nichol
J
J
de la Bastide
Y
Y
Barron
P
P
Hardie
J
J
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004341:Drug Evaluation; D005472:Fluorouracil / Q000008:administration & dosage; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000188:drug therapy; D007822:Laryngeal Neoplasms / Q000188:drug therapy; D008727:Methotrexate / Q000008:administration & dosage; D009062:Mouth Neoplasms / Q000188:drug therapy; D009959:Oropharyngeal Neoplasms / Q000188:drug therapy
D001761:Bleomycin; D003520:Cyclophosphamide; D002945:Cisplatin; D005472:Fluorouracil; D008727:Methotrexate